Galmed Pharmaceuticals Ltd expected to post a loss of 38 cents a share - Earnings Preview

Eocene

03/08/2021 16:49

* Galmed Pharmaceuticals Ltd  GLMD.OQ   GLMD.O  is expected
to show a no change in quarterly revenue when it reports
results on August 5. 
​* Refinitiv's mean analyst estimate for Galmed Pharmaceuticals
Ltd is for a loss of 38 cents per share. For the same quarter
last year, the company reported a loss of 26 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Galmed
Pharmaceuticals Ltd is $14​, about 79.1% above​ its last closing
price of $2.92. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.42       -0.38      -0.38     Met     1.3
 Dec. 31 2020  -0.35       -0.36      -0.48     Missed  -31.9
 Sep. 30 2020  -0.29       -0.30      -0.32     Missed  -6.7​
 Jun. 30 2020  -0.31       -0.32      -0.26     Beat    18.4
 Mar.          -0.35​      -0.37      -0.29     Beat    20.8​
 31​ 2020​                                              
 Dec. 31 2019  -0.27       -0.34      -0.39     Missed  -13.2​
 Sep. 30 2019  -0.29       -0.29      -0.21     Beat    27.9
 Jun. 30 2019  -0.21       -0.22      -0.20     Beat    9.5
 This summary was machine generated August 3 at 15:49 GMT.  All
figures in US dollars unless otherwise stated